Immunome (IMNM) Invested Capital (2019 - 2026)

Immunome has reported Invested Capital for 8 years, with the latest figure at $588.7 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 91.68% year-over-year to $588.7 million; the trailing twelve-month figure through Mar 2026 stood at $588.7 million (up 91.68% YoY), and the FY2025 full-year result was $634.3 million, up 250.15% from the prior year.
• Invested Capital for Q1 2026 stood at $588.7 million, down from $634.3 million in the prior quarter.
• The five-year high for Invested Capital was $634.3 million in Q4 2025, with the low at $6.1 million in Q3 2023.
• Historically, Invested Capital has averaged $191.5 million across 5 years, with a median of $181.2 million in 2024.
• Annual changes were most pronounced in 2023 — Invested Capital plunged 73.68% — and 2024, when it surged 3436.97%.
• Immunome's Invested Capital stood at $16.7 million in 2022, then soared by 619.88% to $119.9 million in 2023, then jumped by 51.12% to $181.2 million in 2024, then surged by 250.15% to $634.3 million in 2025, then decreased by 7.2% to $588.7 million in 2026.
• The last three Invested Capital figures came in at $588.7 million (Q1 2026), $634.3 million (Q4 2025), and $263.9 million (Q3 2025), per Business Quant data.